How Pfizer Became a Value Stock With a 5 Percent Yield

Lucas and Luna explore Pfizer's transformation from growth pharma giant to a value investor's dilemma. With the stock down over 40% from its pandemic peak and now yielding roughly 5%, they debate whether the selloff is overdone or justified. Lucas walks through Pfizer's pipeline math, the patent cliff on 11 drugs through 2030, and the free cash flow yield argument. Luna pushes back on the 'value trap' label, noting the company's $15 billion cost-cutting plan and recent M&A discipline. They touch on the broader rotation into value this year, with the Russell 2000 up nearly 2% in the last week alone, and ask: does a 5% dividend make Pfizer a bond replacement or a falling knife? Specific numbers include the 11 patents expiring, the 5-plus percent dividend yield, and the current P/E of roughly 9.5. No hot takes, just a sober look at one of the most debated large-cap stocks in the value universe. #Pfizer #ValueInvesting #DividendYield #PharmaStocks #PatentCliff #FreeCashFlow #ValueTrap #Biotech #StockMarket #InvestingStrategy #LargeCap #Healthcare #Finance #FexingoBusiness #BusinessPodcast #TheValueInvestingPodcast #LucasAndLuna #LongTermInvesting Keep every episode free: buymeacoffee.com/fexingo